FDA Approved: VITRAKVI — Original Application (Loxo Oncology, Inc.)

View source ↗

Summary

FDA approved VITRAKVI (larotrectinib) for solid tumors that harbor NTRK gene fusions, regardless of tumor site. This tissue-agnostic indication represents a lan…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ntrk Gene Fusion Solid Tumors

Drugs mentioned

• Vitrakvi (larotrectinib)

Snippet

ORIG AP for VITRAKVI (LAROTRECTINIB)